Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Abstract The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF) demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment persistence, effectiveness and safety of dabigatran therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2,500 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 341 SPAF patients receiving dabigatran were enrolled. The combined endpoint of stroke/transient ischaemic attack/systemic embolism occurred at ...
Source: Thrombosis and Haemostasis - March 5, 2015 Category: Hematology Authors: Beyer-Westendorf J, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N Tags: Thromb Haemost Source Type: research

Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.
In conclusion, warfarin treatment where patients spend a high proportion of time in the therapeutic range is safe and effective, and will continue to be a valid treatment option in the era of newer oral anticoagulants. PMID: 25716771 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 26, 2015 Category: Hematology Authors: Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A Tags: Thromb Haemost Source Type: research

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: Insights form the RE-LY trial.
CONCLUSIONS: Anemia is associated with a raised risk of thromboembolic events, bleeding complications and mortality in anticoagulated patients with AF. These findings suggest that patients with anemia should be monitored closely during all types of anticoagulant treatment. This article is protected by copyright. All rights reserved. PMID: 25683276 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 13, 2015 Category: Hematology Authors: Westenbrink BD, Alings M, Connolly SJ, Eikelboom J, Ezekowitz MD, Oldgren J, Yang S, Pongue J, Yusuf S, Wallentin L, van Gilst WH Tags: J Thromb Haemost Source Type: research

Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
CONCLUSION: More than 75% of patients were adherent >80% during the first year. Patients with higher morbidity, including patients with a higher risk of stroke or bleeding, exhibited better adherence. This improvement may be attributable to more regular contact with the health care system. This article is protected by copyright. All rights reserved. PMID: 25594442 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 16, 2015 Category: Hematology Authors: Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA Tags: J Thromb Haemost Source Type: research

Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in nonvalvular atrial fibrillation patients: A multicenter propensity-matched analysis.
CONCLUSIONS: The heparin bridging therapy increased bleeding without the benefit of preventing stroke at the initiation of OAC in NVAF. Our data suggest that heparin bridging should not be considered at the initiation of OAC in NVAF patients. This article is protected by copyright. All rights reserved. PMID: 25472735 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 4, 2014 Category: Hematology Authors: Kim TH, Kim JY, Mun HS, Lee HY, Roh YH, Uhm JS, Pak HN, Lee MH, Joung B Tags: J Thromb Haemost Source Type: research

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients with an elective surgery or procedure. Substudy of the RE-LY trial.
In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption. PMID: 25472710 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 4, 2014 Category: Hematology Authors: Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ Tags: Thromb Haemost Source Type: research

Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP).
In conclusion, a lack of endogenous FSAP impaired the formation of stable, occlusive thrombi in mice. The underlying in vivo effect of FSAP is more likely to be related to the modulation of TFPI rather than FVIIa. PMID: 25427855 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 27, 2014 Category: Hematology Authors: Subramaniam S, Thielmann I, Morowski M, Pragst I, Sandset PM, Nieswandt B, Etscheid M, Kanse SM Tags: Thromb Haemost Source Type: research

Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
In conclusion antiplatelet discontinuation increases the 30-day risk of MACE, in patients with coronary stents undergoing cardiac and non-cardiac surgery, while not offering significant protection from BARC≥ 2 bleeding. PMID: 25274620 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 2, 2014 Category: Hematology Authors: Rossini R, Musumeci G, Capodanno D, Lettieri C, Limbruno U, Tarantini G, Russo N, Calabria P, Romano M, Inashvili A, Sirbu V, Guagliumi G, Valsecchi O, Senni M, Gavazzi A, Angiolillo DJ Tags: Thromb Haemost Source Type: research

Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.
Abstract Anticoagulants are effective at preventing and treating thrombosis, but can cause bleeding. For decades, vitamin K antagonists (VKAs) have been the only available oral anticoagulants. The development of non-VKA oral anticoagulants (NOACs), which inhibit either factor Xa or thrombin stoichiometrically, has provided alternatives to VKAs for several indications. The results of recent large-scale randomised controlled trials comparing NOACs with VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation (AF) have produced some unexpected results. As a group, NOACs showed similar effic...
Source: Thrombosis and Haemostasis - September 4, 2014 Category: Hematology Authors: Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS Tags: Thromb Haemost Source Type: research

Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement.
In conclusion, we found that early after mechanical valve replacement, therapeutic dose bridging was associated with a similar risk of thromboembolic complications, but a 2.5 to 3-fold increased risk of major bleeding compared with prophylactic dose bridging. PMID: 25183209 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 28, 2014 Category: Hematology Authors: Mathew JG, Spyropoulos AC, Yusuf A, Vincent J, Eikelboom J, Shestakovska O, Fremes S, Noora J, Guo L, Peterson M, Pai M, Whitlock R Tags: Thromb Haemost Source Type: research

Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Abstract Acute coronary syndrome (ACS) is a medical emergency. Patients who survive the initial event remain at risk of recurrent cardiovascular events. In most cases, ACS is triggered by thrombosis after rupture of an atherosclerotic plaque. Key to thrombus formation at this site is the generation of thrombin, which not only converts fibrinogen to fibrin but also serves as a potent platelet agonist and induces platelet aggregation at the site of vascular injury. Although dual antiplatelet therapy is more effective for the prevention of recurrent events than aspirin alone after ACS, there remains an approximately ...
Source: Thrombosis and Haemostasis - July 17, 2014 Category: Hematology Authors: Weitz JI Tags: Thromb Haemost Source Type: research

Comparing Mortality in Patients with Atrial Fibrillation who are Receiving a Direct Oral Anticoagulant or Warfarin: A Meta-analysis of Randomized Trials.
CONCLUSION: Compared with warfarin therapy for stroke prevention in patients with AF, DOACs significantly reduce all-cause mortality, vascular mortality and bleeding mortality. This mortality benefit appears to be driven by the reduction in vascular- and bleeding-related mortality which, in turn, may be related to the reduction in intracranial bleeding. This article is protected by copyright. All rights reserved. PMID: 24986568 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 1, 2014 Category: Hematology Authors: Liew A, O'Donnell M, Douketis J Tags: J Thromb Haemost Source Type: research

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial.
CONCLUSION: In anticoagulated patients with AF the level of D-dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D-dimer level. This article is protected by copyright. All rights reserved. PMID: 24942912 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A Tags: J Thromb Haemost Source Type: research

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta-analysis.
CONCLUSION: Mortality in patients treated by thrombolytic therapy for valve prosthesis thrombosis is significantly lower than in patients treated surgically. As we cannot yet ascertain whether this difference is due to the treatment alone, more studies now are necessary to further clarify these findings. This article is protected by copyright. All rights reserved. PMID: 24698327 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 2, 2014 Category: Hematology Authors: Castilho FM, Sousa MR, Mendonça AL, Ribeiro AL, Cáceres-Lóriga FM Tags: J Thromb Haemost Source Type: research

It's not about sex.
This article is protected by copyright. All rights reserved. PMID: 24628770 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 15, 2014 Category: Hematology Authors: Greaves M Tags: J Thromb Haemost Source Type: research